LPN exams cardiovascular practice questions set 17

Correct answer:

The correct answer is B: Inhibition of the hydrolysis of endogenous acetylcholine. Indirect-acting cholinomimetic agents work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine. By inhibiting this enzyme, these agents increase the levels of acetylcholine at the receptor sites, leading to prolonged activation of cholinergic receptors. This mechanism results in enhanced cholinergic effects in the body. Choice A is incorrect because indirect-acting cholinomimetic agents do not directly bind to or activate muscarinic or nicotinic receptors. Choice C is incorrect as these agents do not stimulate the action of acetylcholinesterase; rather, they inhibit its activity. Choice D is incorrect because indirect-acting cholinomimetic agents do not release acetylcholine from storage sites; instead, they prevent its breakdown.

Correct answer:

The correct answer is D. The rationale is as follows: 1. The nurse accurately explains the purpose of the MRI as taking a picture of the brain. 2. The response addresses the patient's concern about pain by stating that the test doesn't hurt. 3. Mentioning the need to lie still covers potential discomfort during the procedure. 4. This response is informative, reassuring, and addresses the patient's questions effectively. Choices A, B, and C are incorrect: A. Incorrect because it inaccurately states the purpose of the MRI and provides false reassurance about pain. B. Incorrect because it wrongly suggests the test is painful and misleadingly focuses on mental illness diagnosis. C. Incorrect because it inaccurately describes the MRI process and its relation to brain activity, leading to confusion and unnecessary worry for the patient.

Correct answer:

The correct answer is D: Αlfa-receptor antagonists. Alpha-receptor antagonists, such as phenoxybenzamine and phentolamine, are used in the management of pheochromocytoma to block the effects of excess catecholamines released by the tumor. These agents help control hypertension and other symptoms associated with pheochromocytoma. A: Selective beta2-receptor antagonists are not typically used in the management of pheochromocytoma because they do not target the alpha-receptors responsible for the symptoms. B: Nonselective beta-receptor antagonists may be used as adjunct therapy in pheochromocytoma to control tachycardia, but they do not directly address the alpha-receptor effects. C: Indirect-acting adrenoreceptor antagonist drugs do not specifically target the alpha-receptors involved in pheochromocytoma symptoms. In summary,

Correct answer:

The correct answer is C: RELA fusion. Ependymomas are known to have specific molecular characteristics, with RELA fusion being a common genetic alteration associated with these tumors. The fusion of RELA gene is a key genetic event in the pathogenesis of supratentorial ependymomas. This fusion leads to the activation of the NF-κB signaling pathway, which is important in the development and progression of ependymomas. Now, let's summarize why the other choices are incorrect: A: BRAFKIAA1549 fusion - This fusion is typically associated with pilocytic astrocytomas, not ependymomas. B: BRAFV600E mutation - This mutation is commonly found in other types of brain tumors like pleomorphic xanthoastrocytomas and gangliogliomas, not ependymomas. D: H3K27M mutation - This mutation is typically seen in diffuse midline gliomas, such as diffuse

Correct answer:

The correct answer is C: Stage III. Rationale: 1. In the St. Jude (Murphy) staging system for non-Hodgkin lymphoma, Stage III is defined as the presence of a mediastinal mass that is greater than 33% of the thoracic diameter. 2. The patient in the scenario has a large mediastinal mass that meets this criteria, placing her in Stage III. 3. The absence of disease in other sites, as confirmed by the metastatic work-up, indicates that the disease is localized to the mediastinum. 4. Therefore, based on the specific criteria of the St. Jude (Murphy) staging system, the correct stage for this patient's non-Hodgkin lymphoma is Stage III. Summary of other choices: - Choice A: Stage I would not be appropriate as the mass is not localized to a single lymph node region. - Choice B: Stage II would not be correct as the mass extends beyond a

Correct answer:

The correct answer is A: Second intercostal space to the right of the sternum. This is where the aortic valve can best be auscultated. Step-by-step rationale: 1. The aortic valve is located in the second intercostal space on the right side of the sternum. 2. Placing the stethoscope at this location allows for optimal sound transmission of the aortic valve. 3. This area corresponds to the anatomical location of the aortic valve, making it the most accurate site for assessment. Summary of other choices: B: Second intercostal space to the left of the sternum - Incorrect as the aortic valve is on the right side. C: Fourth intercostal space to the left of the sternum - Incorrect, as this is the location for the mitral valve. D: Fifth intercostal space in the midclavicular line - Incorrect, as this is the location for the mitral valve.

Correct answer:

The correct answer is A: Pulmonary hypertension. Pulmonary hypertension refers to the condition where the walls of the arteries in the lungs become thickened and stiff, leading to increased blood pressure in the pulmonary arteries. This results in the heart having to work harder to pump blood through the lungs, causing potential damage to the heart and lungs over time. B: Pulmonary fibrosis is a condition characterized by scarring of lung tissue, not thickening and stiffening of artery walls. C: Pulmonary embolism is a blockage in one of the pulmonary arteries in your lungs, usually caused by a blood clot. It does not involve thickening and stiffening of artery walls. D: Pulmonary edema is a condition where fluid builds up in the lungs, causing difficulty in breathing. It is not related to thickened and stiffened artery walls.

Correct answer:

Rationale for Correct Answer (A): Myelosuppression requiring growth factor and blood product support is the most likely adverse event following [131]I-MIBG therapy due to its impact on bone marrow. The therapy targets neuroblastoma cells, but can also affect normal bone marrow function, leading to myelosuppression. Growth factors and blood products are often needed to support hematopoiesis. Summary of Incorrect Answers: B: Severe mucositis: Not a common adverse event associated with [131]I-MIBG therapy, as it primarily affects the bone marrow. C: Hemorrhagic cystitis: Not directly related to [131]I-MIBG therapy, which does not typically cause bladder toxicity. D: Symptomatic hypothyroidism: While [131]I-MIBG therapy can affect thyroid function, symptomatic hypothyroidism is not the most likely adverse event following this therapy.

Correct answer:

The correct answer is B because the principal aim for treating Parkinsonian disorders is to restore dopaminergic activity with levodopa and dopamine agonists. This is because Parkinson's disease is primarily caused by a deficit of dopamine in the brain. Levodopa is converted to dopamine in the brain, helping to alleviate symptoms. Choice A is incorrect because antimuscarinic drugs target the cholinergic system, not the dopaminergic system, and are not the primary treatment for Parkinson's disease. Choice C is incorrect because glutamate antagonists target a different neurotransmitter system and are not the mainstay of treatment for Parkinson's disease. Choice D is incorrect because while restoring balance between cholinergic and dopaminergic influences may be important, the primary aim is to address the dopaminergic deficit.

Correct answer:

The correct answer is D: Inhibiting cyclooxygenase action in platelets. Aspirin inhibits cyclooxygenase, specifically COX-1, in platelets, leading to the inhibition of thromboxane A2 production. Thromboxane A2 is a potent platelet aggregator. By inhibiting its production, aspirin reduces platelet aggregation, thus reducing the risk of cardiovascular events. A: Activating thromboxane A2 - This is incorrect because aspirin actually inhibits the production of thromboxane A2. B: Blocking adenosine diphosphate receptor agonists - This is incorrect because aspirin primarily works through the inhibition of cyclooxygenase, not adenosine diphosphate receptors. C: Suppressing specific clotting factors - This is incorrect because aspirin's primary mechanism of action is through platelet inhibition, not through suppressing clotting factors.